Share on StockTwits

Brainstorm Cell Therapeutics (NASDAQ:BCLI) major shareholder International Holdings Ltd Acc purchased 150,000 shares of the company’s stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $0.35 per share, for a total transaction of $52,500.00. Following the acquisition, the insider now directly owns 1,389,600 shares in the company, valued at approximately $486,360. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded down 6.10% during mid-day trading on Monday, hitting $0.285. 1,054,196 shares of the company’s stock traded hands. Brainstorm Cell Therapeutics has a one year low of $0.10 and a one year high of $0.37. The stock’s 50-day moving average is $0.27 and its 200-day moving average is $0.24. The company’s market cap is $52.1 million.

BrainStorm Cell Therapeutics Inc is a biotechnology company developing autologous stem cell therapies for highly debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (NASDAQ:BCLI) (Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD) and Spinal Cord Injury.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.